---
trigger_pattern: "A defensive/relative-strength Healthcare call is already correctly read as a reversal—negative 1d/3d relative tape plus a growth/tech-led tape unwinding the prior defensive bid—but S1 is left at 0 because the policy category was checked too superficially as “nothing material,” while a same-day drug-pricing/policy overhang is actually live in sector media. The result is a directionally correct but magnitude-understated down/flat call where the actual is down/mild."
current_behavior: "When the reversal direction is clear, S1 is defaulted to 0 if no obvious catalyst was pre-fetched; the predicted band then settles on flat, producing direction_hit True but magnitude_hit False."
corrected_behavior: "When a reversal call is already confirmed by S2/S4 tape, run a same-day audit of policy/regulatory headlines before scoring S1=0. If a live negative policy/pricing narrative targets mega-cap pharma/insurers (drug-cost executive orders, record price-drop claims, combination-shot cost warnings, etc.), score S1 at least -0.5 and select the mild band rather than flat. Use flat only if the policy audit is genuinely neutral."
evidence_cited: "2026-08-14: predicted down/flat; actual XLV -0.60% vs SPY -0.20% (rel -0.40). Direction hit, magnitude missed. S1 was 0 despite same-day pharma-trade reporting that the combination-shot separation EO “will drive up drugmaker costs” and that drug prices recorded their biggest YoY drop; CNBC’s wrap also named healthcare as an explicit laggard. A -0.5 S1 would have shifted the output to the mild band and matched the actual."
error_category: "B"
falsifier: "If a future Healthcare call in the exact confirmed-reversal + live drug-pricing-overhang setup closes within ±0.3% (flat) or higher, the “policy overhang ⇒ mild-down” rule will be disconfirmed and should be softened back to flat-centering."
sector: "Healthcare"
date: "2026-08-14"
status: "candidate"
---

# Sector Reflection — Healthcare — 2026-08-14

LESSON_BEGIN
ERROR_CATEGORY: B
TRIGGER_PATTERN: A defensive/relative-strength Healthcare call is already correctly read as a reversal—negative 1d/3d relative tape plus a growth/tech-led tape unwinding the prior defensive bid—but S1 is left at 0 because the policy category was checked too superficially as “nothing material,” while a same-day drug-pricing/policy overhang is actually live in sector media. The result is a directionally correct but magnitude-understated down/flat call where the actual is down/mild.
CURRENT_BEHAVIOR: When the reversal direction is clear, S1 is defaulted to 0 if no obvious catalyst was pre-fetched; the predicted band then settles on flat, producing direction_hit True but magnitude_hit False.
CORRECTED_BEHAVIOR: When a reversal call is already confirmed by S2/S4 tape, run a same-day audit of policy/regulatory headlines before scoring S1=0. If a live negative policy/pricing narrative targets mega-cap pharma/insurers (drug-cost executive orders, record price-drop claims, combination-shot cost warnings, etc.), score S1 at least -0.5 and select the mild band rather than flat. Use flat only if the policy audit is genuinely neutral.
EVIDENCE: 2026-08-14: predicted down/flat; actual XLV -0.60% vs SPY -0.20% (rel -0.40). Direction hit, magnitude missed. S1 was 0 despite same-day pharma-trade reporting that the combination-shot separation EO “will drive up drugmaker costs” and that drug prices recorded their biggest YoY drop; CNBC’s wrap also named healthcare as an explicit laggard. A -0.5 S1 would have shifted the output to the mild band and matched the actual.
LESSON_MATCH_CHECK: The active 08-13 healthcare reversal lesson is directionally confirmed by this run, but no existing lesson captures the S1-remains-0-while-a-live-policy-overhang-exists magnitude miss. This is an extension, not a duplicate.
BACKWARD_CHECK: On 08-13 healthcare—the same reversal setup—the corrected S1 policy audit would have pushed the call further down/mild, which aligns better with the actual flat/negative result. In the graded window, no prior healthcare case had this exact live-policy-overhang-in-confirmed-reversal signature, so the correction introduces no regression.
CONFLICT_CHECK: No conflict with the 08-13 reversal lesson, which explicitly permits flat-to-mild; this rule just resolves the flat-vs-mild choice when a second negative factor is present in S1. It is also consistent with the freshness lessons because this is a same-day/live policy item, not a stale April MA-rate catalyst.
FALSIFIER: If a future Healthcare call in the exact confirmed-reversal + live drug-pricing-overhang setup closes within ±0.3% (flat) or higher, the “policy overhang ⇒ mild-down” rule will be disconfirmed and should be softened back to flat-centering.
DIVERGENCE_VERDICT: none_flagged
ACTIVE_LESSON_REVIEW: Retain the 08-13 healthcare reversal lesson as the primary direction rule; add a mandatory S1 policy/pricing audit when choosing flat vs mild. The 08-14 basic-materials/energy lessons about over-anchoring to prior tape are not implicated here because the direction was correct; the gap was data coverage on the sector-factor side.
SECTOR: Healthcare
LESSON_END
